Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-11-10 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an 'RNS Number' filing from the London Stock Exchange, which is a primary indicator of a regulatory announcement. The title 'TR-1: Standard form for notification of major holdings' and the content detailing changes in voting rights (falling below the 5% threshold) by UBS Group AG specifically match the criteria for a Major Shareholding Notification. Although RNS is mentioned, the specific nature of the content points directly to the 'MRQ' category, which covers notifications of changes in significant share ownership levels (crossing thresholds). The document is a formal notification of a change in holding, not a general regulatory filing fallback (RNS) or a report itself.
2023-11-10 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and contains the header "PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" under "Rule 8.3 of the Takeover Code (the “Code”)". This form is used to disclose interests and dealings in the securities of an offeror or offeree during a takeover process, which falls under regulatory disclosure related to M&A activity or significant shareholdings during a bid. While it relates to share ownership, the specific context of Rule 8.3 of the Takeover Code strongly suggests it is related to a takeover or merger situation. Given the options, this type of mandatory disclosure during a takeover bid is most closely aligned with M&A Activity (TAR) or a specific regulatory filing. Since it is a specific disclosure mandated by the Takeover Code regarding interests in securities during a potential offer, it is a specialized regulatory filing. However, since the document details the positions and dealings of a major shareholder (Millennium International Management LP) concerning an offeree (Dechra Pharmaceuticals plc) under the Takeover Code, it is a direct consequence of M&A activity. If 'TAR' (Takeover Activity Report) is interpreted broadly to cover disclosures related to ongoing takeover bids, it fits best. If we strictly follow the definitions, it is a specific regulatory disclosure. Given the context of the Takeover Code, it is a disclosure related to a potential takeover. I will classify it as M&A Activity (TAR) as it is directly tied to the takeover process governed by the Code, although it is also a form of regulatory disclosure.
2023-11-09 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document explicitly starts with "RNS Number : 9857S" and contains the header information typical of a regulatory filing disseminated via the London Stock Exchange's news service (RNS). The content details a "TR-1: Standard form for notification of major holdings" by Barclays PLC regarding an acquisition or disposal of voting rights, crossing a threshold. This type of mandatory disclosure regarding significant changes in share ownership falls under the category of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a notification of a change in major shareholding, making MRQ the most precise classification over the general RNS fallback.
2023-11-09 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with "RNS Number : 9855S" and contains the header "National Storage Mechanism". The content details a "TR-1: Standard form for notification of major holdings" by Societe Generale regarding an acquisition of voting rights in Dechra Pharmaceuticals PLC. This type of mandatory disclosure concerning changes in significant share ownership thresholds is a specific regulatory filing. While it relates to shareholding, the specific form (TR-1) and context point directly to a Major Shareholding Notification, which corresponds to code MRQ. Although RNS is mentioned as the distribution service, the core content is the notification itself, not just an announcement of a report.
2023-11-09 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with "RNS Number : 9364S" and contains the standard footer indicating it is provided by RNS, the news service of the London Stock Exchange. The content details a "TR-1: Standard form for notification of major holdings" concerning an acquisition or disposal of voting rights by Bank of America Corporation/Merrill Lynch International. This type of mandatory disclosure regarding changes in significant share ownership thresholds directly corresponds to the Major Shareholding Notification category.
2023-11-09 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and contains the header 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is used by parties involved in a takeover bid to disclose their interests and dealings in the relevant securities. This type of disclosure, related to insider transactions during a takeover scenario, is best classified under Director's Dealing (DIRS) as it involves reporting personal share transactions/interests by significant parties, although it is specifically mandated by the Takeover Code. Given the options, DIRS covers personal transactions by insiders/significant holders. Since it is a specific regulatory disclosure about holdings and dealings, and not a general regulatory announcement (RNS) or a report on management remuneration (DEF 14A), DIRS is the most appropriate fit among the provided codes for insider transaction reporting.
2023-11-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.